Although it has been recognized that Mycobacterium tuberculosis contains large amounts of Tolllike receptor 2 (TLR2) ligands, their direct effects on CD4 + T cells and the clinical implications have not been determined.
that TLR variants contribute to human susceptibility to tuberculosis. In terms of TLR2, Chang et al [2] have reported that M. tuberculosis infection causes up-regulation of TLR2 in the mononuclear leukocytes of patients with active tuberculosis. TLR2 polymorphisms in human are associated with increased susceptibility to tuberculosis [4, 6] , and TLR2-deficien mice die rapidly after M. tuberculosis infection [7] .
M. tuberculosis expresses numerous TLR2 ligands, such as 19-kDa lipoprotein and the lipoprotein LprA. The interactions between TLR2 and M. tuberculosis 19-kDa lipoprotein, LprA, or live M. tuberculosis have multiple effects on the phenotypic and functional regulation of TLR2-expressing macrophages and dendritic cells, for example, the expression of HLA-DR and response to interferon g (IFN-g) [8] [9] [10] [11] [12] . However, these studies have focused on the role played by TLR2 in innate immune cells in tuberculosis. Whether M. tuberculosis may directly modulate adaptive immune responses through TLR2 remains unclear. In particular, the effects that M. tuberculosis-derived TLR2 ligands have on TLR2-expressing CD4
+ T cells and their clinical implications require further investigation.
Recent finding have shown that CD4 + T cells express some TLRs that may regulate T cell activity independently of antigenpresenting cells (APCs) [13] [14] [15] [16] [17] . TLR2, expressed on activated T cells, may increase cellular proliferation and IFN-g secretion after T cell receptor (TCR) stimulation [17, 18] . Because CD4 + T lymphocytes play a critical role in controlling M. tuberculosis infection and are predominant among the immune cells inf ltrating the pleural flui in patients with tuberculosis [19] [20] [21] [22] [23] [24] , we sought to determine the direct effects that M. tuberculosis TLR2 ligands have on CD4 + T lymphocytes infi trating into tuberculous pleura. We hypothesized that M. tuberculosis and its TLR2 ligands may modulate the function and survival of CD4 + T cells during M. tuberculosis infection, which may in turn facilitate local CD4 + T cell responses observed in patients with tuberculous pleurisy.
METHODS

Patients and samples.
Thirty-nine patients with newly diagnosed pulmonary tuberculosis and 22 patients with tuberculous pleurisy were prospectively recruited at Shenzhen Third Hospital, Shenzhen, China. The diagnosis was based on positive cultures for M. tuberculosis, clinical and radiological features, and a good response to antituberculosis treatment.
For comparison, 38 healthy donors were recruited in this study. Regular physical examinations, bacillus Calmette-Guérin (BCG) purifie protein derivative skin test, and M. tuberculosis antigen-specifi IFN-g enzyme-linked immunospot assay were used to exclude those with latent M. tuberculosis infection.
All participants were from the Chinese Han ethnic population. Mean ages were 38.3 years (range, 21-58 years) for patients with pulmonary tuberculosis, 33.2 years (range, 20-59 years) for patients with tuberculous pleurisy, and 30.2 years (range, 22-59 years) for healthy donors. The male-to-female ratios for the 3 groups were 26:13, 15:7, and 20:18, respectively. For both patient groups, the white blood cell counts in blood ranged from to cells/L, and lymphocyte 9 9 4.53 ϫ 10 10.57 ϫ 10 counts ranged from to cells/L. For patients 9 9 1.14 ϫ 10 2.79 ϫ 10 with tuberculous pleurisy, the cell numbers in pleural f uid ranged from to cells/L. The white blood 6 6 0.35 ϫ 10 1.21 ϫ 10 cell and lymphocyte counts for healthy donors were within normal ranges for healthy individuals ( to 9 9 4.0 ϫ 10 10.0 ϫ 10 cells/L and to cells/L, respectively). 9 9 1.5 ϫ 10 4.0 ϫ 10 Protocols were approved by the Institutional Review Board of Shenzhen Third Hospital. Written informed consent was obtained from all participants. Participants were screened for human immunodeficienc virus, hepatitis B virus, or hepatitis C virus infection by an enzyme-linked immunosorbent assay (ELISA) diagnostic kit (provided by Beijing WanTai), and patients with positive results were excluded from our study. Blood and pleural flui samples were collected before or within 1 week after antituberculosis treatment.
T cell purificatio and analysis. Peripheral blood mononuclear cells (PBMCs) and pleural flui mononuclear cells (PFMCs) were obtained as described elsewhere [25] . The plasma and supernatant of pleural flui was stored at Ϫ80ЊC for further use. CD3 + CD4
+ T lymphocytes were isolated from PBMCs or PFMCs by depletion of non-CD4 + T cells, using magnetic-activated cell sorting (Miltenyi Biotec), in accordance with the manufacturer's instructions. The purity of the isolated cells was routinely 195%, as determined by fl w cytometry.
Purifie CD4 + T cells were subsequently cultured for 3 days in complete Roswell Park Memorial Institute 1640 medium (Hyclone) in the presence of 1 mg/mL plate-bound anti-CD3 and anti-CD28 antibodies (eBioscience), with or without TLR2 ligands. Unless indicated otherwise, TLR2 ligands were used at the following concentrations: 19-kDa lipoprotein, 0.5 mg/mL (Lionex); Pam3Cys-SK4, 0.5 mg/mL (Invitrogen); live BCG, 10 mg/mL (equivalent to colony-forming units/mL; Si- 4 1 ϫ 10 chuan Bio-Product); and recombinant hepatitis B virus surface antigen, 10 mg/mL (Kangtai Biotechnology). After 3 days of culturing, the cells were harvested for flo cytometry analysis. The supernatants were collected for quantificatio of cytokine production by ELISA. Blocking anti-TLR2 (clone TL2.1) and immunoglobulin G isotype control antibodies (eBioscience) were used to evaluate the specifi role of TLR2.
Flow cytometry analysis. Monoclonal antibodies against CD3 (clone SK7), CD4 (clone SK3), CD8 (clone SK1), TCRab (clone WT31), CD14 (clone MFP9), CD27 (clone L128), CD38 (clone HB7), CD44 (clone L178), HLA-DR (clone 243), CD69 (clone UCHL1), CD45RO (clone 78), IFN-g (clone 25723.11), and isotype-matched control immunoglobulin were obtained from BD Biosciences. Anti-human TLR2-APC (clone TL2.1) or isotype control monoclonal antibodies (mAbs) were obtained from eBioscience. Apoptosis of cultured CD4 + T cells was identifie by flo cytometry after cells were stained with fluo escent annexin V (Bender MedSystems), in accordance with the manufacturer's instructions, and by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) technology with the In Situ Cell Death Detection kit (Roche Diagnostics). To detect intracellular IFN-g, PFMCs from patients with tuberculous pleurisy were stimulated with the indicated TLR2 ligands for 72 h. Cells were exposed to brefeldin A (10 mg/mL; Sigma-Aldrich) for 6 h before collection, stained with anti-CD3 and anti-CD8 antibodies, f xed and permeabilized with Cytofix/Cytope m Plus (BD Biosciences), and then stained with anti-IFN-g antibody before being analyzed by flo cytometry. A minimum of 100,000 events were acquired with a BD FACSCanto flo cytometer and analyzed using BD FACSDiva software (version 5.0.2; BD Biosciences). Carboxyfluo escein succinimidyl ester staining and cell proliferation assay. To measure cell proliferation in response to TLR2 ligands, purifie CD4 + T cell suspensions were labeled with carboxyfluo escein succinimidyl ester (CFSE) at a fi al concentration of 1.25 mmol/L. Cells were incubated at 37ЊC for 10 min and washed twice. Cells were then resuspended in complete medium, and cells/well were cultured for 3 days RNA isolation and reverse transcription. Total RNA was extracted from purifie CD4 + T cells isolated from fresh PBMCs and PFMCs by means of an RNeasy Mini kit (Qiagen). RNA was reverse transcribed using a SensiScript reverse transcriptase kit (Qiagen) and oligo(dT)15 (Takara) with 20 ng of RNA as the starting material (ϫ10 reverse-transcriptase buffer, 0.5 mmol/L deoxyribonucleotide triphosphate, 10 U of RNase inhibitor, 1 mmol/L oligo(dT)15, 10 U of reverse transcriptase, and RNase-free water).
Quantitative real-time polymerase chain reaction. The following primers and probe for TLR2 were used: forward, 5 -AGAGTGAGTGGTGCAAGTATGAA-3 ; reverse, 5 -AATG GCAGCATCATTGTTCTC-3 ; and probe, 5 -TGGACTTCTCC CATTTCCGT-3 . Primers and probes were synthesized by Shanghai GeneCore BioTechnologies. The housekeeping gene b-actin was used as a reference, as described elsewhere [21] . Complementary DNA was amplifie by quantitative real-time polymerase chain reaction (PCR) using the ABI 7500 real-time PCR detection system (ABI). Relative messenger RNA (mRNA) expression compared with b-actin mRNA molecules was calculated using a method that has been described elsewhere [26] .
Chemotaxis assay. CD4 + T cells isolated from PFMCs were plated ( cells/mL) in 96-well plates. Cells were treated 6 1 ϫ 10 with Pam3Cys-SK4, 19-kDa lipoprotein, or BCG with anti-CD3 and anti-CD28 mAbs and incubated for 48 h at 37ЊC. Chemotaxis assays were then performed as described elsewhere [27] . Briefl , cell migration was assessed with a modif ed transwell chamber assay; CD4 + T cells ( cells/mL in 0.1 mL 6 1 ϫ 10 of medium) were seeded in the upper compartment of a transwell chamber (5-mm-pore size; Corning Costar). Interleukin 8 (IL-8) (10 ng/mL) was introduced in the bottom well of the chamber, with untreated wells used as a control. After incubation for 3 h at 37ЊC, cells were recovered from the bottom chambers and counted. A chemotaxis index was determined for each treatment, define as the number of migrating cells in response to each treatment divided by the number of migrating cells with no treatment.
Detection of cytokine by ELISA. IFN-g, interleukin 17 (IL-17), interleukin 4 (IL-4), IL-8, and interleukin 2 (IL-2) concentrations in culture supernatants were determined using sandwich DuoSet ELISA kits, in accordance with the manufacturer's instructions (R&D Systems). TLR2 ligand activity assay. Human embryonic kidney (HEK) 293 cells transfected with human TLR2 gene (HEK293-hTLR2) were obtained from InvivoGen. In response to stimulation with TLR2, HEK293-hTLR2 cells secrete IL-8 [11] . The activity of TLR2 ligands was thus assessed by measuring IL-8 production in the supernatant of stimulated HEK293-hTLR2 cells [11] . Serum and pleural flui were incubated with HEK293-hTLR2 cells, and the production of IL-8 was quantif ed by ELISA.
Statistical analyses. One-way analysis of variance with the Newman-Keuls multiple-comparison test was used to compare the differences between multiple groups (GraphPad Prism software; version 3.0). The Wilcoxon matched-pair t test was used to analyze the effect of TLR2 ligand treatment on CD4 + T cells. Differences were considered signifi ant at . P ! .05
RESULTS
Increased TLR2 expression by CD4
+ T lymphocytes in patients with active tuberculosis. Previous reports have indicated that M. tuberculosis infection is associated with an increase in TLR2 mRNA expression by PBMCs [2] . To determine more specifically the expression profil of TLR2 by CD4 + T cells, we evaluated TLR2 mRNA levels in CD4 + T cells isolated from fresh PBMCs and PFMCs. Our results indicated that TLR2 mRNA levels were significantl increased in CD4 + T cells from patients with tuberculosis, compared with levels for healthy donors. In addition, TLR2 mRNA expression was significantl higher in CD4 + T cells isolated from PFMCs than in CD4 + T lymphocytes from the blood of patients with tuberculosis (fi ure 1A).
The percentage of activated CD4 + T lymphocytes (cells expressing CD27, CD45RO, HLA-DR) that expressed TLR2 was significantl higher than the percentage in resting CD4 + T cells, as determined by flo cytometry (figu e 1B and data not shown). TLR2 expression by both activated and resting CD4 + T cells was significantl increased in patients with tuberculosis, compared with that in healthy donors (figu e 1B-1D). TLR2 expression by CD3 + CD4 + T cells was significantl higher than that in CD3 + CD4 Ϫ T cells among PFMCs and PBMCs (fi ure 1B and data not shown). Increased TLR2 ligand activity at the site of infection in patients with tuberculosis. TLR2 ligand activity in the serum and pleural flui samples was determined using HEK293-hTLR2 cells, which produce IL-8 in response to TLR2 agonists. We firs established that HEK293-hTLR2 cells produced significan amounts of IL-8 in response to stimulation with Pam3Cys-SK4, M. tuberculosis-derived 19-kDa lipoprotein, and live BCG in a dose-dependent manner, but not in response to hepatitis B surface antigen (HBsAg) (used to rule out non-TLR2 stimulation) (figu e 2A and 2B). We then directly quantifie the levels of IL-8 in blood samples obtained from healthy donors and patients with tuberculosis and in pleural fl id from patients with tuberculosis (figu e 2C). Consistent with previous reports [28, 29] , we found that IL-8 was significantl increased in pleural flui samples from patients with tuberculosis. HEK293-hTLR2 cells were then treated with serum or pleural flui samples, and IL-8 production was evaluated by ELISA. For each sample, the IL-8 concentration was corrected by subtracting the values shown in figu e 2C (IL-8 background in the patient serum or pleural flui sample). The data depicted in figu e 2D indicate that TLR2 ligand activity was significantl higher in tuberculous pleural flui than in serum samples from healthy donors or from patients with pulmonary tuberculosis.
Modulation of cytokine production of CD4 + T cells from PFMCs by M. tuberculosis TLR2 ligands. Although M. tuberculosis TLR2 ligands did not directly affect TLR2 expression by CD4
+ T cells, they may be capable of modulating the activity of these lymphocytes [18] . Our results indicate that the TLR2 not significant It is possible that 19-kDa lipoprotein differs kinetically from other TLR2 ligands or that the concentration used was less than the optimal concentration required to induce strong migration of CD4 + T cells.
DISCUSSION
We have demonstrated in this study that TLR2 expression by CD4 + T cells was significantl increased in patients with tuberculosis, compared with that for healthy donors. In addition, M. tuberculosis-derived 19-kDa lipoprotein and live BCG directly promoted the function of activated CD4 + T cells. These results extend previous finding indicating that PBMCs from patients with tuberculosis expressed higher levels of TLR2 mRNA. We have also provided evidence that CD4 + T lymphocytes infiltratin the pleural flui expressed higher levels of TLR2 than did circulating CD4 + T cells. These fi dings are consistent with previous reports indicating that surface TLR2 expression can be induced by TCR engagement and activation [17] . Activated CD3 + CD4 + T cells isolated from blood or pleural flui expressed higher levels of TLR2 than did nonactivated resting CD4 + T cells. Most of the activated CD4 + cells purif ed from PFMCs expressed TCR-ab, HLA-DR, and CD27 but not CD14, and, unlike their circulating counterparts, they exhibited a memory or activated phenotype. It is important to note that the pathogen itself (and the TLR agonists it contains) may upregulate TLR2 expression through TLR ligation [30] . This may be relevant, because TLR2 ligand activities were significantl higher in tuberculous pleural flui than in serum from healthy donors or patients with pulmonary tuberculosis. However, our results indicate that in vitro activation with TLR2 ligands of CD4 + T cells isolated from PFMCs (in the presence or absence of APCs) did not affect TLR2 expression (data not shown). This suggests that the induction of TLR2 expression by direct stimulation with TLR2 ligands is negligible.
Although M. tuberculosis TLR2 ligands were able to enhance IFN-g production by both CD4 + and CD8 + T cells from PFMCs, the response of CD4 + T cells was greater than that of CD8 + T lymphocytes. Although the precise explanation for this difference remains unclear, this result reflect the predominance of CD4 + over CD8 + T cell responses in patients with tuberculous pleurisy and may be explained by differences between CD4 + and CD8 + T cells in TLR2 expression and pathway signaling [31] .
The predominance and expansion of the CD4 + T lymphocyte population in the pleura of patients with tuberculous pleurisy could be due to enhanced proliferation and survival of CD4 + T cells. We confi med that M. tuberculosis TLR2 ligands promoted the proliferation and survival of CD4 + T cells isolated from PFMCs. Interestingly, these effects of TLR2 ligands on the proliferation and survival of CD4 + T cells were observed only when purifie CD4 + T cells were concomitantly activated with anti-CD3 and anti-CD28. One possible explanation was that M. tuberculosis and its associated TLR2 ligands indirectly affect CD4 + T cells by activating macrophages or other APCs contained among PFMCs. This possibility was ruled out, however, because TLR2 agonists were able to modulate highly purifi d CD4 + T cells from PFMCs. Recruitment of TLR2-expressing CD4 + T cells may account for the observed increased frequency of these cells in the pleura. Our results indicated that M. tuberculosis TLR2 ligands enhanced the migration of activated CD4 + T cells toward an IL-8 source. This is significant because IL-8 levels are elevated in the pleural flui of patients with tuberculosis and because chemotaxis toward IL-8 has been identifie as an important mechanism for lymphocytic infiltratio of the pleura during tuberculosis [28, 29] . CD4 + T lymphocytes represent a heterogeneous population of cells that include Th1 and Th2 cells, regulatory T cells, and Th17 cells [32] . All of these cells have been shown to participate in the immune response against tuberculosis. Although we were not able to evaluate the effect of TLR2 ligands on each individually purifie subset of CD4 + T cells, our observation that 19-kDa lipoprotein and live BCG modulated IFN-g but not IL-4 production suggests that M. tuberculosis-derived TLR2 ligands may have different effects on Th1 and Th2 CD4 + T cells. This result is consistent with a previous report indicating that TLR2 directly promotes the effector function of Th1 but not Th2 cells [18] . In addition, by demonstrating that TLR2 agonists triggered IL-17 production by CD4 + T cells, our study provides further information on the modulatory effects of these ligands on Th17 cells. Because Th1 and Th17 cells have been shown to be critical mediators of the protective immunity against tuberculosis, additional studies are warranted to clarify the in vitro and in vivo function of TLR2 for these cells [33] [34] [35] .
